// App-Quantinova.ai

: Establishment and Characterization of a Model of Acquired Resistance to DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic Leukemia Cells

Researchers

Presenter

  • Pauline Schneider

Principal Investigators

  • Susan T.C.J.M. Arentsen-Peters

  • Nicholas T. Crump

  • Alastair Smith

  • Rico Hagelaar

  • Fabienne R.S. Adriaanse

  • Romy S. Bos

  • Kirsten S. Vrenken

  • Dedeke rockx-Brouwer

  • Ziqin Tang

  • Wilbert P. Vermeij

  • Anja De Jong

  • Bianca Koopmans

  • M.Emmy M. Dolman

  • Thomas A. Milne

  • Rob Pieters

  • Ronald W. Stam

Medical Centers

  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

  • Dutch Oncology Group, Utrecht, NLD

  • Oncode Institute, Utrecht, Netherlands

  • MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

Locations

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Acute Leukemia

Biomarkers

  • AF4/FMR2 Family Member 1

  • Breakpoint Cluster Region

  • C-C Motif Chemokine Ligand 5

  • cMYC

  • Cluster of Differentiation 38

  • Cyclin dependent kinase 6

  • Prominin 1

  • G protein subunit alpha q

  • Homeobox A9

Drug/Treatment

  • Pinometostat

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved